A predictive model that incorporates the androgen receptor concentration of prostate cancer cells can identify patients who have an increased risk of clinical failure 5 years after radical prostatectomy.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Postoperative Urinary Retention – AUGS Publications Committee Interview
September 26th 2023Dr. Kate Meriwether, AUGS Publications Committee member, interviews Dr Colleen McDermott, the first author of the Clinical Consensus Statement “Postoperative Urinary Retention,” to provide an overview and highlight the findings of the document.
2 Clarke Drive
Cranbury, NJ 08512